Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More Ovarian cancer is the malignancy with the highest rate of death from tumors of the female ...

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment ...

TIGIT (T-cell immunoreceptor with Ig and ITIM domains) has emerged as a promising target in cancer immunotherapy due to its critical role in suppressing T-cell-mediated anti-tumor immune responses.

Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

Indeed, there is clinical evidence to suggest that restoring p53 can induce an anti-cancer immune response in immunologically cold tumors. Clinical trials investigating the combination of ...

Prof. MENG Guangxun's team from the Shanghai Institute of Immunity and Infection of the Chinese Academy of Sciences, and collaborators, have revealed a novel mechanism whereby a short form of IL-18, ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV ...

Cancer immunotherapy is a therapy used to treat ... Here the authors report the results of a phase 1a trial of TILT-123 combined with anti-PD1 pembrolizumab in patients with platinum resistant ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy have developed ...

Researchers at Penn Medicine have created a cancer treatment which could reshape cancer immunotherapy. Credit: Devansh Raniwala Researchers at Penn ... “This new strategy has a number of advantages ...